Rituximab FDA Link

A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.

Also Known As:

Mabthera; Rituxan; CD20 Antibody, Rituximab; GP2013; IDEC-C2B8; IDEC-C2B8 Antibody; IDEC C2B8; IDEC C2B8 Antibody; Rituximab CD20 Antibody

Amino Acids, Peptides, and Proteins: 1
- Proteins: 496323
  - Blood Proteins: 12679
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Murine-Derived Monoclonal Antibodies: 1
        Rituximab: 15896
    - Immunoproteins: 43
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Murine-Derived Monoclonal Antibodies: 1
        Rituximab: 15896
  - Globulins: 3119
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Murine-Derived Monoclonal Antibodies: 1
        Rituximab: 15896

Sujatha Vuyyuru Selected Research

Sujatha Vuyyuru Research Topics

Disease

Drug/Important Bio-Agent (IBA)